Vericel Q2 Revenue Jumps 20%

Vericel (NASDAQ:VCEL), a cell therapy specialist focused on sports medicine and burn care, reported its Q2 2025 results on July 31, 2025. The most headline-worthy news was the 20% year-over-year GAAP revenue growth, driven strongly by its MACI franchise, and a substantial gross margin gain to 74%. Revenue (GAAP) reached $63.2 million, up from $52.7 million (GAAP) in Q2 2024, but missed analyst expectations of $64.5 million (GAAP). Net loss per share (GAAP) narrowed to $0.01, handily topping the estimated GAAP loss of $0.03 per share. Overall, the quarter showed steady growth and healthy margin expansion, despite falling slightly short on sales targets, with GAAP revenue of $63.2 million missing the analyst estimate of $64.48 million. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Vericel operates in regenerative medicine, developing and manufacturing advanced cell therapy products in the United States. Its main products are MACI, a cartilage repair implant for knee injuries; Epicel, a skin graft for severe burns; and NexoBrid, an enzymatic product for removing dead tissue in burn patients. Each is approved by the U.S. Food and Drug Administration and is sold to hospitals and specialist surgeons.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool